Royal Bank of Canada
BDTX icon

Royal Bank of Canada’s Black Diamond Therapeutics BDTX Stock Holding History

Royal Bank of Canada’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
699
-293
-30% -$697 ﹤0.01% 6828
2025
Q4 		$2K Buy
992
+933
+1,581% +$3.3K ﹤0.01% 6886
2025
Q3 		$0 Sell
59
-104,934
-100% -$307K ﹤0.01% 7129
2025
Q2 		$260K Buy
104,993
+104,299
+15,029% +$201K ﹤0.01% 4965
2025
Q1 		$1K Buy
+694
New +$1.46K ﹤0.01% 6629
2024
Q4 		– Sell
-12,355
Closed -$54K – 6893
2024
Q3 		$54K Buy
12,355
+8,861
+254% +$48.2K ﹤0.01% 5658
2024
Q2 		$16K Buy
+3,494
New +$18.8K ﹤0.01% 6148
2024
Q1 		– Sell
-2,866
Closed -$8K – 7011
2023
Q4 		$8K Buy
+2,866
New +$6.72K ﹤0.01% 6541
2023
Q3 		– Sell
-1,355
Closed -$7K – 7077
2023
Q2 		$7K Buy
1,355
+1,160
+595% +$2.37K ﹤0.01% 6562
2023
Q1 		$0 Hold
195
– – ﹤0.01% 7071
2022
Q4 		$0 Sell
195
-176
-47% -$317 ﹤0.01% 7215
2022
Q3 		$0 Sell
371
-324
-47% -$999 ﹤0.01% 7438
2022
Q2 		$1K Sell
695
-1,076
-61% -$2.5K ﹤0.01% 7088
2022
Q1 		$5K Sell
1,771
-3,215
-64% -$11.7K ﹤0.01% 7240
2021
Q4 		$27K Buy
4,986
+2,492
+100% +$17.4K ﹤0.01% 6656
2021
Q3 		$21K Buy
2,494
+935
+60% +$9.23K ﹤0.01% 6671
2021
Q2 		$19K Buy
1,559
+165
+12% +$3.26K ﹤0.01% 6582
2021
Q1 		$34K Buy
1,394
+1,000
+254% +$27K ﹤0.01% 6119
2020
Q4 		$13K Buy
394
+377
+2,218% +$12.4K ﹤0.01% 6254
2020
Q3 		$1K Sell
17
-11
-39% -$335 ﹤0.01% 6391
2020
Q2 		$1K Sell
28
-459
-94% -$16.9K ﹤0.01% 6382
2020
Q1 		$12K Buy
+487
New +$14.8K ﹤0.01% 5750

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Royal Bank of Canada's BDTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Black Diamond Therapeutics (BDTX) stake by 30% in Q1 2026, selling an estimated $697 and leaving 699 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6828.

Royal Bank of Canada first reported a position in BDTX in Q1 2020 and has held it in 22 quarters since. The position peaked at $260K in Q2 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Royal Bank of Canada held 699 shares of Black Diamond Therapeutics worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 293 Black Diamond Therapeutics shares in Q1 2026, an estimated $697.
  • Black Diamond Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6828 holding.
  • Royal Bank of Canada first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's Black Diamond Therapeutics position peaked at $260K in Q2 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.